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A B S T R A C T
Raloxifene hydrochloride therapy effectiveness in bone mineral density (BMD) changes compared to calcium and vi-
tamin D3 therapy over a 2-year period. Case-control study: a group of 254 women was prescribed raloxifene (raloxifene
hydrochloride) together with calcium and vitamin D3 while other group of 254 women used calcium and vitamin D3
therapy. BMD was measured at the hip, spine and forearm at the beginning and at the end of the 2-year period. Treat-
ment with raloxifene resulted in a 3.7% increase in BMD at the spine in 98% of examinees. A 1.2% BMD increase was
shown in 75% of examinees at the hip. A 1.2% decrease in BMD at forearm shown in 93% of examinees using raloxifene.
The calcium and vitamin D3 therapy led to an increase in BMD in 58% examinees at the spine, in 56% at the hip and in
38% at the forearm, which was significantly lower than in women using raloxifene. Among women using calcium and
vitamin D alone an average BMD decrease of 1.2% was registered on 42% of examinees at the spine, 2.6% decrease on
46% of examinees at the hip and 4.2% decrease on 35% of examinees at the forearm. Treatment with raloxifene resulted
in a significant increase in BMD at the spine with odds ratio (OR 5.85, p<0.05) compared with calcium and vitamin D3
alone. There was no statistically proven increase in BMD at either the hip (OR 0.015) or forearm (OR 0.122).
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Introduction
One of the most represented metabolic diseases of the
bone in the world is osteoporosis; its incidence is equal as
that of cardiovascular and malignant diseases. It is known
that risk of developing osteoporosis and severe complica-
tions as fractions increase with age. World population
structure is getting older and by that the risk of fractures
tends to increase. Fractures of the spine, forearm and the
hip are the most frequent. Commonly induced by post-
menopausal osteoporosis fractures of the spine are fre-
quent in middle-aged women. Fractures of the hip, which
are commonly induced by senile osteoporosis, are linked
with: high mortality (25%), high long-term loss of func-
tion (25%) and lesser quality of life (50%)1–3.
Society is trying to deal and coup with osteoporosis
with raising awareness and education, acquiring and de-
veloping diagnostic tools, as well as developing new drugs
and treatments. Currently on the market there is a vari-
ety of medications to prevent osteoporotic fractures.
Raloxifene is a first drug from the group of selective
estrogen receptor modulators that has proven its effi-
ciency in prevention and treatment of postmenopausal
osteoporosis4,5. Its effects on 76% decrease of breast can-
cer incidence6 and reduction of the overall cardiovascular
risk is well known7–13. It is confirmed that raloxifene sig-
nificantly decreases vertebral and non-vertebral fractu-
ring14,15.
Aim of this scientific paper is to determine changes in
the bone mineral density in a case control study of group
postmenopausal women who were prescribed raloxifene,
calcium and vitamin D3 and a group of those who were
prescribed only calcium and vitamin D3. Both groups of
women were compatible by age, BMD, BMI and age of
starting menopause. Study was done in a 2-yrs period.
Subjects and Methods
All examinees were split into two statistically equal
groups – for further details see Table 1.
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1. Study group was consisted of 254 women who had ta-
ken 60 mg of raloxifene (Eli Lilly Co. Ltd., Basingsto-
ke, England), 1000 mg of calcium and 800 units of vi-
tamin D3 per day over a 2-yr period.
2. Control group was consisted of 254 women who recei-
ved only 1000 mg of calcium and 800 units of vitamin
D3 per day throughout the same period.
3. The average age in both groups was 57 years. We mon-
itored the effects on new vertebral and non-vertebral
fractures. All women had been informed and had given
their consent to the research by signing an informed
consent form. Ethics Committee of the General hospi-
tal »Dr. Josip Ben~evi}«, Sl.Brod approved this study
Questionnaire handed out to examinees asked for in-
formation concerning daily intake of milk products,
first and last menstrual period, family history of osteo-
porosis, tobacco intake and physical inactivity longer
then 3 months. Before starting with the study/treat-
ment examination of the BMD at the hip, vertebra and
the forearm were conducted. Levels of calcium and
phosphorus in the serum and 24h urine, alkaline-
phosphatase, total cholesterol and tryglicerides were
collected.
There was no statistically significant difference de-
tected between of the control and study group after
pre-treatment examinations. In both groups there was
no vertebral fractures; during the 2-yr period every ver-
tebral and non-vertebral fracture was reported. In the
study group there were 9 fractures of the forearm, while
in the control group 10 forearm fractures were detected.
In both groups, during 2-yr period wasn’t fractures of the
hip and the vertebra detected.
BMD was measured by dual-energy X-ray absorptio-
metry with QDR 4500 densitometer (Hologic, Beresford,
MA, USA) and the results were expressed in g/cm2; for
both groups at the beginning and end of the 2-year period.
Mean percentage changes in BMD at the both groups
were determined and odds ratio (OR) was calculated. The
statistical significance was tested using the chi square
test and set to p<0.05. All statistics were performed us-
ing Statistica for Windows software, Version 6.0 (Tulsa,
OK, USA).
Results
Raloxifene improved the spinal bone density in 98% of
examinees. Hip BMD increased in 75% of cases whereas a
decrease in density occurred at the forearm in 93% of
examinees. The spine BMD increased from 0.807 g/cm2
(±0.103) to 0.836 (±0.298), which was a 3.7% increase.
BMD increased at the hip, from 0.813 (±0.125) to 0.821
(±0.09) that represented a 1.2% increase. However, the
forearm BMD decreased from 0.615 (±0.071) to 0.541
(±0.073) that was a 1.2% decrease.
Calcium and vitamin D3 therapy led to an increase in
BMD in 58% of examinees at the spine from 0.791 (±0.025)
to 0.800 (±0.011) which is an 1.2% increase.
In 56% of examinees increase at the hip is 0,9% – from
0.783 (±0.025) to 0.790 (±0.014). In the forearm increase
is an 0.8% in 38% of examinees- from 0.601 (±0.021) to
0.605 (±0.006).
A decrease in BMD was manifested in 42% of exa-
minees at the spine area, 46% at the hip, and 35% at the
forearm area. A decrease in BMD at the spine, hip and
forearm was 1.6%, 2.6% and 4.2%, respectively (Table 2).
There were significantly more examinees with signifi-
cant increase in bone density of the spine among raloxi-
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TABLE 1
CLINICAL CHARACTERISTICS OF THE STUDY GROUPS
Variables
N (%) of postmenopausal women
Study group (n=254) Control group (n=254)
Age, X±SD 56.1±7.9 56.1±7.9
Menarche, X±SD 14.7±2 14.4±1.7
Menopause, X±SD 47.8±5.7 47.9±5.2
Family history of osteoporosis 4 (1.57) 5 (1.96)
Immobility 7 (2.7) 8 (3.1)
Body mass index (BMI), X±SD 29.3±4.5 28.3±4.1
Smoking 30 (11.8) 32 (12.6)
Milk consumption < 500 ml 60 (23.6) 58 (22.8)
Serum Calcium, X±SD 2.7±2.4 2.4±0.2
Serum Phosphorus, X ±SD 1.1±0.3 1.1±0.6
Serum Alkaline Phosphatase, X±SD 69.2±22 73.5±26.4
Urine Calcium, X±SD 5.7±3.2 5.7±3.6
Urine Phosphorus, X±SD 24.4±15.4 23.9±10.1
Total Cholesterol, X±SD 6.6±1.5 6.1±1.2
Tryglicerids, X±SD 1.9±1.6 1.8±0.8
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fene group than among women using calcium and vita-
min D3 alone, while in hip and the forearm the difference
was not significant. Chi-square values of 24.67 (p<0.05)
for spinal BMD with OR 5.58 and CI 95% (1.535–53.967)
were calculated. For the hips the 2 value was 43.14 with
OR 0.0105 and CI 95% (0.0160–0.896), for the forearm
the 2 value was 27.86 with OR 0.122 and CI 95%
(0.0021–0.0568).
Discussion
Raloxifene increases total bone density, especially at
the spine. Some authors indicate increase of the bon den-
sity at the hip as well13–16. Results of our research were
similar to those of earlier conducted research. We de-
tected a slight improvement of the BMD at the hip and
forearm. During the period of the study we detected no
fractures of the hip. In the study group we have regis-
tered 9 and in the control group 10 fractures of the fore-
arm, which difference was not statistically significant. In
this age group of our examinees we found no fractures of
the spine, probably due to raloxifene therapy. Monitoring
the effects of these therapies in a longer period of time
probably would have shown significant difference be-
tween vertebral and non-vertebral fractures. Significant
differences of the efficiency of preventing fractures were-
n’t and could not have been detected due to the younger
age of women in study group.
Raloxifene improved significantly spine bone density.
A 2.4% increase in BMD at the lumbar spine and hip and
a 2% increase in total bone mass following 2 years of
therapy was previously reported14. Etinger et al.15 found
a 2.6% increase in BMD at the spine and a 2.1% increase
in BMD at the hips following 36 months of therapy.
Zheng et al.16 found an increase of 2.3% in BMD at the
spine and 2.5% at the hip area. Our results were consis-
tent with most of these previously conducted studies on
Caucasian or Asian women.
Our study showed insignificant positive effects of vi-
tamin D and calcium therapy on the spine only, while a
decrease in bone density at hip and forearm was re-
vealed. However, the BMD decrease at forearm was lower
among this group of women. Evidence by other research-
ers has shown how intake of calcium and vitamin D pre-
vented the risk of bone density decrease at all areas17.
Our study had several limitations, the most impor-
tant of them being the case-control design of the study.
More relevant data, with possibility of definite conclu-
sion could be yielded through a prospective randomized
study. However, our place of work lacks organization and
financial potentials for that kind of investigation. It
would also be interesting to prospectively investigate the
risk of fractures in these two groups of women.
Irrespective of age, raloxifene has advantages in pa-
tients who have a higher risk of breast and endometrial
cancer, as well as those with medium hypercholeste-
rolemia10. Raloxifene therapy is the good solution for
both treatment and prevention of early postmenopausal
osteoporosis.
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TABLE 2
EFFECTS OF RALOXIFENE THERAPY AND CALCIUM AND VITAMIN D THERAPY ON BMD IN THE HIP, SPINE AND FOREARM
THROUGHOUT A 2-YEAR PERIOD





Spine In the begining 0.807±0.103 0.791±0.025
After 2-yrs 0.836±0.298 0.800±0.011
Hip In the begining 0.813±0.125 0.783±0.025
After 2-yrs 0.821±0.821 0.790±0.014
Forearm In the begining 0.615±0.615 0.580±0.501
After 2-yrs 0.541±0.073 0.556±0.451
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UTJECAJ RALOKSIFENA NA PROMJENE KO[TANE GUSTO]E
S A @ E T A K
Kroz dvije godine je uspore|en utjecaj raloksifen hidroklorida (raloksifena) na promjenu ko{tane gusto}e (BMD) u
odnosu na kalcij i vitamin D3. »Case control« studija je obuhva}ala dvije skupine po 254 `ene, od kojih su jedne kroz 2.
godine uzimale raloksifen, kalcij i vitamin D3, a druge samo kalcij i vitamin D3. Ko{tana gusto}a je mjerena na kuku,
kralje{nici i podlaktici na po~etku i nakon 2. godine terapije. Tretman raloksifenom je pove}ao ko{tanu gusto}u za 3,7%
na kralje{nici kod 98% ispitanica. Pove}anje gusto}e na kuku je bilo 1,2% kod 75% ispitanica. Pad ko{tane gusto}e je bio
za 1,2% na podlaktici kod 93% ispitanica uz raloksifen. Terapija kalcijem i vitaminom D3 je pove}ala ko{tanu gusto}u
kod 58% ispitanica na kralje{nici, 56% na kuku i 38% na podlaktici {to je zna~ajno ni`e u odnosu na skupinu lije~enu
raloksifenom. U skupini lije~enoj kalcijem i vitaminom D3 zabilje`en je prosje~ni pad ko{tane gusto}e na kralje{nici za
1,2% kod 42% ispitanica, na kuku za 2,6% kod 46% ispitanica te za 4,2% na podlaktici kod 35% ispitanica. Terapija
raloksifenom zna~ajno pove}ava ko{tanu gusto}u na kralje{nici (OR 5.85, p<0.05) u odnosu na terapiju samo kalcijem i
vitaminom D3. Nema statisti~ke zna~ajnosti u pove}anju ko{tane gusto}e na kuku (OR 0.015) ni podlaktici (OR 0,122).
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